Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,778 full-time employees. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Mr. Olivier Loeillot es el President de Repligen Corp, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción RGEN?
El precio actual de RGEN es de $114.49, ha disminuido un 1.59% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Repligen Corp?
Repligen Corp pertenece a la industria Life Sciences Tools & Services y el sector es Health Care
¿Cuál es la capitalización bursátil de Repligen Corp?
La capitalización bursátil actual de Repligen Corp es $6.4B
¿Es Repligen Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 18 analistas han realizado calificaciones de análisis para Repligen Corp, incluyendo 7 fuerte compra, 16 compra, 5 mantener, 0 venta, y 7 fuerte venta